Milestone Net Debt vs Gross Profit Margin Analysis

MIST Stock

USD 1.94 0.04 2.02%

Milestone Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Milestone Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Milestone Pharmaceuticals is a good investment. Please check the relationship between Milestone Pharmaceuticals Net Debt and its Gross Profit Margin accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Milestone Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy Milestone Stock please use our How to Invest in Milestone Pharmaceuticals guide.

Net Debt vs Gross Profit Margin

Net Debt vs Gross Profit Margin Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Milestone Pharmaceuticals Net Debt account and Gross Profit Margin. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Milestone Pharmaceuticals' Net Debt and Gross Profit Margin is -0.49. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Gross Profit Margin in the same time period over historical financial statements of Milestone Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Milestone Pharmaceuticals' Net Debt and Gross Profit Margin is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Milestone Pharmaceuticals are associated (or correlated) with its Gross Profit Margin. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Gross Profit Margin has no effect on the direction of Net Debt i.e., Milestone Pharmaceuticals' Net Debt and Gross Profit Margin go up and down completely randomly.

Correlation Coefficient

-0.49

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Gross Profit Margin

Most indicators from Milestone Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Milestone Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Milestone Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy Milestone Stock please use our How to Invest in Milestone Pharmaceuticals guide.At this time, Milestone Pharmaceuticals' Sales General And Administrative To Revenue is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 207.7 M in 2024, whereas Selling General Administrative is likely to drop slightly above 10.4 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Income	220K	1.3M	3.5M	3.7M
Net Interest Income	220K	1.3M	1.8M	1.2M

Interest Income Net Interest Income

Milestone Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Net Working Capital
Total Assets		0.68	0.9	0.86	0.88	0.58	-0.56	-0.63	0.96	0.77	0.58	-0.6	1.0	0.33	0.81	0.37	0.57	-0.53	0.58	0.83	0.76	-0.48	0.89	0.59	1.0	1.0
Other Current Liab	0.68		0.91	0.62	0.7	0.79	-0.25	-0.75	0.74	0.48	0.79	-0.79	0.66	0.5	0.8	0.47	0.61	-0.47	0.67	0.7	0.4	-0.42	0.69	0.8	0.67	0.65
Total Current Liabilities	0.9	0.91		0.8	0.89	0.79	-0.37	-0.81	0.95	0.64	0.79	-0.8	0.88	0.54	0.92	0.53	0.65	-0.55	0.74	0.82	0.68	-0.5	0.88	0.8	0.89	0.88
Total Stockholder Equity	0.86	0.62	0.8		0.96	0.64	-0.54	-0.57	0.84	0.66	0.64	-0.59	0.86	0.14	0.87	0.39	0.68	-0.85	0.53	0.84	0.78	-0.82	0.97	0.65	0.86	0.86
Net Tangible Assets	0.88	0.7	0.89	0.96		0.75	-0.36	-0.74	0.91	0.57	0.75	-0.74	0.87	0.4	0.95	0.52	0.73	-0.82	0.7	0.87	0.82	-0.79	1.0	0.77	0.88	0.87
Property Plant And Equipment Net	0.58	0.79	0.79	0.64	0.75		0.11	-0.91	0.66	0.11	1.0	-0.97	0.53	0.62	0.9	0.79	0.72	-0.6	0.85	0.86	0.62	-0.56	0.74	1.0	0.57	0.55
Net Debt	-0.56	-0.25	-0.37	-0.54	-0.36	0.11		-0.18	-0.45	-0.93	0.11	-0.21	-0.59	0.52	-0.22	0.23	-0.03	0.19	0.19	-0.23	-0.26	0.16	-0.38	0.09	-0.57	-0.58
Retained Earnings	-0.63	-0.75	-0.81	-0.57	-0.74	-0.91	-0.18		-0.74	-0.13	-0.91	0.97	-0.59	-0.82	-0.87	-0.85	-0.54	0.51	-0.98	-0.81	-0.72	0.48	-0.73	-0.93	-0.62	-0.6
Accounts Payable	0.96	0.74	0.95	0.84	0.91	0.66	-0.45	-0.74		0.72	0.66	-0.68	0.95	0.48	0.89	0.48	0.59	-0.53	0.68	0.81	0.79	-0.48	0.91	0.69	0.96	0.95
Cash	0.77	0.48	0.64	0.66	0.57	0.11	-0.93	-0.13	0.72		0.11	-0.06	0.8	-0.17	0.46	-0.03	0.17	-0.26	0.11	0.41	0.45	-0.22	0.58	0.14	0.78	0.78
Non Current Assets Total	0.58	0.79	0.79	0.64	0.75	1.0	0.11	-0.91	0.66	0.11		-0.97	0.53	0.62	0.9	0.79	0.72	-0.6	0.85	0.86	0.62	-0.56	0.74	1.0	0.57	0.55
Non Currrent Assets Other	-0.6	-0.79	-0.8	-0.59	-0.74	-0.97	-0.21	0.97	-0.68	-0.06	-0.97		-0.55	-0.77	-0.86	-0.78	-0.68	0.57	-0.92	-0.84	-0.62	0.54	-0.73	-0.97	-0.58	-0.57
Cash And Short Term Investments	1.0	0.66	0.88	0.86	0.87	0.53	-0.59	-0.59	0.95	0.8	0.53	-0.55		0.29	0.78	0.32	0.55	-0.51	0.54	0.8	0.74	-0.47	0.87	0.55	1.0	1.0
Net Receivables	0.33	0.5	0.54	0.14	0.4	0.62	0.52	-0.82	0.48	-0.17	0.62	-0.77	0.29		0.52	0.56	0.41	-0.15	0.77	0.4	0.35	-0.13	0.38	0.63	0.32	0.3
Common Stock Total Equity	0.81	0.8	0.92	0.87	0.95	0.9	-0.22	-0.87	0.89	0.46	0.9	-0.86	0.78	0.52		0.69	0.72	-0.73	0.82	0.9	0.81	-0.69	0.94	0.91	0.8	0.79
Common Stock Shares Outstanding	0.37	0.47	0.53	0.39	0.52	0.79	0.23	-0.85	0.48	-0.03	0.79	-0.78	0.32	0.56	0.69		0.19	-0.39	0.91	0.72	0.75	-0.37	0.51	0.81	0.36	0.34
Short Term Investments	0.57	0.61	0.65	0.68	0.73	0.72	-0.03	-0.54	0.59	0.17	0.72	-0.68	0.55	0.41	0.72	0.19		-0.64	0.39	0.63	0.32	-0.62	0.73	0.69	0.56	0.55
Non Current Liabilities Total	-0.53	-0.47	-0.55	-0.85	-0.82	-0.6	0.19	0.51	-0.53	-0.26	-0.6	0.57	-0.51	-0.15	-0.73	-0.39	-0.64		-0.51	-0.67	-0.62	1.0	-0.83	-0.6	-0.52	-0.52
Capital Surpluse	0.58	0.67	0.74	0.53	0.7	0.85	0.19	-0.98	0.68	0.11	0.85	-0.92	0.54	0.77	0.82	0.91	0.39	-0.51		0.79	0.77	-0.48	0.69	0.88	0.57	0.55
Other Current Assets	0.83	0.7	0.82	0.84	0.87	0.86	-0.23	-0.81	0.81	0.41	0.86	-0.84	0.8	0.4	0.9	0.72	0.63	-0.67	0.79		0.84	-0.64	0.87	0.86	0.82	0.82
Other Stockholder Equity	0.76	0.4	0.68	0.78	0.82	0.62	-0.26	-0.72	0.79	0.45	0.62	-0.62	0.74	0.35	0.81	0.75	0.32	-0.62	0.77	0.84		-0.6	0.82	0.66	0.76	0.76
Total Liab	-0.48	-0.42	-0.5	-0.82	-0.79	-0.56	0.16	0.48	-0.48	-0.22	-0.56	0.54	-0.47	-0.13	-0.69	-0.37	-0.62	1.0	-0.48	-0.64	-0.6		-0.8	-0.57	-0.48	-0.47
Net Invested Capital	0.89	0.69	0.88	0.97	1.0	0.74	-0.38	-0.73	0.91	0.58	0.74	-0.73	0.87	0.38	0.94	0.51	0.73	-0.83	0.69	0.87	0.82	-0.8		0.76	0.88	0.88
Property Plant And Equipment Gross	0.59	0.8	0.8	0.65	0.77	1.0	0.09	-0.93	0.69	0.14	1.0	-0.97	0.55	0.63	0.91	0.81	0.69	-0.6	0.88	0.86	0.66	-0.57	0.76		0.58	0.56
Total Current Assets	1.0	0.67	0.89	0.86	0.88	0.57	-0.57	-0.62	0.96	0.78	0.57	-0.58	1.0	0.32	0.8	0.36	0.56	-0.52	0.57	0.82	0.76	-0.48	0.88	0.58		1.0
Net Working Capital	1.0	0.65	0.88	0.86	0.87	0.55	-0.58	-0.6	0.95	0.78	0.55	-0.57	1.0	0.3	0.79	0.34	0.55	-0.52	0.55	0.82	0.76	-0.47	0.88	0.56	1.0

Click cells to compare fundamentals

Milestone Pharmaceuticals Account Relationship Matchups

Milestone Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	123.4M	150.0M	119.8M	74.5M	75.2M	103.5M
Other Current Liab	3.6M	1.3M	2.2M	3.4M	2.7M	2.5M
Total Current Liabilities	8.3M	6.2M	6.8M	6.1M	7.2M	6.4M
Total Stockholder Equity	114.9M	143.1M	112.6M	66.3M	16.8M	15.9M
Net Tangible Assets	114.9M	143.1M	112.6M	66.3M	76.3M	63.9M
Property Plant And Equipment Net	929K	1.3M	926K	2.7M	2.2M	1.3M
Net Debt	(119.3M)	(71.4M)	(113.4M)	(5.1M)	38.0M	39.9M
Retained Earnings	(113.5M)	(163.5M)	(206.3M)	(266.3M)	(326.0M)	(309.7M)
Accounts Payable	4.4M	4.6M	4.4M	2.3M	4.0M	3.6M
Cash	119.8M	72.3M	114.1M	7.6M	13.8M	13.1M
Non Current Assets Total	929K	1.3M	926K	2.7M	2.2M	1.3M
Non Currrent Assets Other	(929K)	(1.3M)	(926K)	(2.7M)	(2.4M)	(2.3M)
Cash And Short Term Investments	119.8M	142.3M	114.1M	64.6M	66.0M	97.4M
Net Receivables	836K	948K	483K	1.2M	3.9M	4.0M
Common Stock Total Equity	2.0M	226.2M	251.7M	251.9M	289.7M	161.3M
Common Stock Shares Outstanding	15.8M	29.3M	41.8M	42.5M	43.0M	34.5M
Liabilities And Stockholders Equity	123.4M	150.0M	119.8M	74.5M	75.2M	103.5M
Non Current Liabilities Total	184K	696K	474K	2.0M	51.2M	28.9M
Capital Surpluse	2.7M	3.8M	8.5M	15.7M	18.1M	19.0M
Inventory	(578K)	(725K)	(356K)	(331K)	(297.9K)	(312.8K)
Other Current Assets	2.4M	6.2M	4.7M	6.3M	3.2M	3.8M
Other Stockholder Equity	3.8M	56.5M	68.7M	24.4M	33.8M	29.7M
Total Liab	8.5M	6.9M	7.2M	8.1M	58.5M	33.5M
Net Invested Capital	114.9M	143.1M	112.6M	66.3M	66.5M	65.2M
Property Plant And Equipment Gross	978K	1.3M	1.2M	2.7M	2.4M	1.3M
Total Current Assets	122.5M	148.7M	118.9M	71.8M	73.0M	102.2M
Net Working Capital	114.2M	142.5M	112.1M	65.7M	65.8M	95.8M
Short Term Debt	330K	245K	224K	495K	546K	289.1K
Common Stock	226.2M	251.7M	251.9M	273.9M	260.5M	199.2M
Property Plant Equipment	929K	1.3M	215K	2.7M	3.1M	3.2M
Capital Stock	226.2M	251.7M	251.9M	273.9M	260.5M	232.1M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Milestone Stock Analysis

When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC